

Aurobindo Pharma to acquire Natrol for \$132.5 Mn

03 December 2014 | News | By BioSpectrum Bureau

Aurobindo Pharma to acquire Natrol for \$132.5 Mn



The bid is valued at US\$132.5 million.

Natrol manufactures and sells nutritional supplements in the US and other international market.

This acquisition is subject to final approval by the US Court and other statutory approvals as may be required, including any termination of the waiting period or approval under the HSR Act, and closing conditions as per the Asset Purchase Agreement.

Barclays acted as the sole financial advisor, and Sullivan & Cromwell LLP acted as the legal counsel to Aurobindo USA.

This announcement does not constitute a recommendation to the shareholders or potential investors.